These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 19200866)

  • 1. Concepts of induction and escalation therapy in multiple sclerosis.
    Rieckmann P
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S42-5. PubMed ID: 19200866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term experience with induction treatment regimens in multiple sclerosis.
    Le Page E; Edan G
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S46-9. PubMed ID: 19200867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppression followed by immunomodulation.
    Boggild M
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S50-4. PubMed ID: 19200868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?
    Bar-Or A; Oger J; Gibbs E; Niino M; Aziz T; Renoux C; Alatab S; Shi FD; Campagnolo D; Jalili F; Rhodes S; Yamashita T; Fan B; Freedman MS; Panitch H; Arnold DL; Vollmer T
    Mult Scler; 2009 Aug; 15(8):959-64. PubMed ID: 19667022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction versus escalation therapy.
    Martinelli V; Comi G
    Neurol Sci; 2005 Dec; 26 Suppl 4():S193-9. PubMed ID: 16388357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current disease-modifying treatment of multiple sclerosis.
    Derwenskus J
    Mt Sinai J Med; 2011; 78(2):161-75. PubMed ID: 21425262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological treatment of multiple sclerosis].
    Myhr KM
    Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
    Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
    Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximising therapeutic outcomes in patients failing on current therapy.
    Caon C
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S33-6. PubMed ID: 19200864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH
    Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advances in the treatment of multiple sclerosis?].
    Tackenberg B; Himmerich H; Wellek A; Oertel WH; Sommer N
    MMW Fortschr Med; 2007 May; 149 Suppl 2():51-5. PubMed ID: 17724968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis: interferon beta for some serious forms.
    Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis.
    Ytterberg C; Johansson S; Andersson M; Olsson D; Link H; Holmqvist LW; von Koch L
    Acta Neurol Scand; 2007 Aug; 116(2):96-9. PubMed ID: 17661794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
    Vollmer T; Panitch H; Bar-Or A; Dunn J; Freedman MS; Gazda SK; Campagnolo D; Deutsch F; Arnold DL
    Mult Scler; 2008 Jun; 14(5):663-70. PubMed ID: 18424479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for the use of mitoxantrone in multiple sclerosis.
    Edan G; Morrissey S; Le Page E
    J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current therapeutic recommendations in multiple sclerosis.
    Berger T
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S37-45. PubMed ID: 20106347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis.
    Jeffery DR
    J Neurol Sci; 2004 Aug; 223(1):41-6. PubMed ID: 15261559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.